8-K Announcements
6Material company update
Apr 14, 2026·SEC
Material company update
Apr 3, 2026·SEC
Material company update
Mar 30, 2026·SEC
Advanced Biomed Inc. Common Stock(ADVB)Earnings, Financials & Key Ratios
ADVB•NASDAQ
$7.11
$154M mkt cap·Price updated May 6, 2026
AboutAdvanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies and provides them for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, a fully automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cells (CTCs) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also provides microfluidic biochips comprising A+Pre, AC-1000 CTC Enrichment, and A+CellScan chips that are designed to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include the A+CTCE kit, which is used to identify epithelial circulating tumor cells and is determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; the A+CTCM kit, which is used to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; the A+EMT, which is used to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and the A+CM, which is used to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.Show more
- Revenue$0
- EBITDA-$83K+96.1%
- Net Income-$102K+96.4%
- EPS (Diluted)-0.00+96.6%
- ROE-0.01%+100.0%
- ROIC-0.02%
- Debt/Equity0.00-99.5%
ADVB Key Insights
Advanced Biomed Inc. Common Stock (ADVB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading at only 0.0x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ADVB Price & Volume
Advanced Biomed Inc. Common Stock (ADVB) stock price & volume — 10-year historical chart
Loading chart...
ADVB Growth Metrics
Advanced Biomed Inc. Common Stock (ADVB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-2.24%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-2.02%
Return on Capital
10 Years-115.41%
5 Years-115.41%
3 Years-96.07%
Last Year-0.01%
ADVB Recent Earnings
Advanced Biomed Inc. Common Stock (ADVB) EPS & revenue vs analyst estimates — last 4 quarters
Q1 2026Latest
Feb 13, 2026EPS
$0.32
Revenue
—
Q4 2025
Nov 19, 2025EPS
$0.02
Revenue
—
Q4 2025
Oct 8, 2025EPS
$0.03
Revenue
—
Q2 2025
May 15, 2025EPS
$0.07
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 13, 2026 | $0.32 | — |
| Q4 2025 | Nov 19, 2025 | $0.02 | — |
| Q4 2025 | Oct 8, 2025 | $0.03 | — |
| Q2 2025 | May 15, 2025 | $0.07 | — |
Based on last 12 quarters of dataView full earnings history →
ADVB Peer Comparison
Advanced Biomed Inc. Common Stock (ADVB) competitors in Lab Consumables and Sample Preparation — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 KROS | 438.47M | 11.78 | 5.12 | 67.75% | 35.65% | 14.25% | 0.06 | |
 TGTX | 6.7B | 41.97 | 15.15 | 87.32% | 65.95% | 87.36% | 0.40 | |
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 PRTA | 601.85M | 11.18 | -2.47 | -92.84% | -25.21% | -73% | 0.05 | |
 BIIB | 28.15B | 190.68 | 21.59 | 1.39% | 13.92% | 7.55% | 0.38 | |
 ALNY | 40.43B | 303.00 | 130.04 | 65.19% | 13.46% | 98.29% | 1.62 |
Compare ADVB vs Peers
Advanced Biomed Inc. Common Stock (ADVB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ADVB Income Statement
Advanced Biomed Inc. Common Stock (ADVB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 17.2K |
| Revenue Growth % | - | - | - | - | - | - |
| Cost of Goods Sold | 2.03K | 4.48K | 11.89K | 12.55K | 10.71K | 9.13K |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | -2.03K▲ 0% | -4.48K▼ 120.4% | -11.89K▼ 165.5% | -12.55K▼ 5.6% | -10.71K▲ 14.7% | -9.13K▲ 0% |
| Gross Margin % | - | - | - | - | - | -53.07% |
| Gross Profit Growth % | - | -120.43% | -165.53% | -5.57% | 14.65% | - |
| Operating Expenses | 1.84M | 2.37M | 3.07M | 2.54M | 83.4K | 595.14K |
| OpEx % of Revenue | - | - | - | - | - | - |
| Selling, General & Admin | 44.47K | 624.77K | 1.32M | 1.26M | 2.11B | 2.11B |
| SG&A % of Revenue | - | - | - | - | - | - |
| Research & Development | 1.73M | 1.62M | 1.38M | 880.19K | 909.77M | 737.43K |
| R&D % of Revenue | - | - | - | - | - | - |
| Other Operating Expenses | 57.85K | 130.07K | 365.23K | 399.6K | -3.02B | -2.13M |
| Operating Income | -1.84M▲ 0% | -2.37M▼ 29.3% | -3.07M▼ 29.3% | -2.54M▲ 17.2% | -94.11K▲ 96.3% | -1.41M▲ 0% |
| Operating Margin % | - | - | - | - | - | -8191.97% |
| Operating Income Growth % | - | -29.26% | -29.35% | 17.25% | 96.3% | - |
| EBITDA | -1.78M | -2.25M | -2.71M | -2.14M | -83.4K | -1.23M |
| EBITDA Margin % | - | - | - | - | - | -7140.22% |
| EBITDA Growth % | - | -26.34% | -20.39% | 20.84% | 96.11% | 50.32% |
| D&A (Non-Cash Add-back) | 57.85K | 126.63K | 365.23K | 399.6K | 10.71K | 180.9K |
| EBIT | -1.84M | -2.37M | -3.07M | -2.54M | -101.53K | -1.32M |
| Net Interest Income | 28 | 243 | 21.4K | 53.49K | 776 | 15.74K |
| Interest Income | 28 | 243 | 21.4K | 53.49K | 776 | 15.74K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -218 | -1.65M | -661.55K | -240.71K | -7.41K | -918.43K |
| Pretax Income | -1.84M▲ 0% | -4.03M▼ 119.2% | -3.73M▲ 7.3% | -2.78M▲ 25.5% | -101.52K▲ 96.4% | -2.33M▲ 0% |
| Pretax Margin % | - | - | - | - | - | -13531.65% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -1.84M▲ 0% | -4.03M▼ 119.2% | -3.73M▲ 7.3% | -2.78M▲ 25.5% | -101.52K▲ 96.4% | -2.33M▲ 0% |
| Net Margin % | - | - | - | - | - | -13531.65% |
| Net Income Growth % | - | -119.24% | 7.32% | 25.46% | 96.35% | -2.24% |
| Net Income (Continuing) | -1.84M | -4.03M | -3.73M | -2.78M | -101.52K | -2.33M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.16▲ 0% | -0.28▼ 75.0% | -0.19▲ 32.1% | -0.14▲ 26.3% | -0.00▲ 96.6% | -0.11▲ 0% |
| EPS Growth % | - | -75% | 32.14% | 26.32% | 96.64% | -2.02% |
| EPS (Basic) | -0.16 | -0.28 | -0.19 | -0.14 | -0.00 | - |
| Diluted Shares Outstanding | 11.46M | 14.18M | 19.94M | 20M | 21.64M | 21.64M |
| Basic Shares Outstanding | 11.46M | 14.18M | 19.93M | 20M | 21.64M | 21.64M |
| Dividend Payout Ratio | - | - | - | - | - | - |
ADVB Balance Sheet
Advanced Biomed Inc. Common Stock (ADVB) balance sheet — assets, liabilities & shareholders' equity
| Line item | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|
| Total Current Assets | 913.5K | 5.01M | 2.79M | 3.05M | 6.03B | 5.84M |
| Cash & Short-Term Investments | 65.92K | 4.78M | 2.62M | 2.61M | 2.9B | 2.66M |
| Cash Only | 65.92K | 4.78M | 2.62M | 2.61M | 2.9B | 2.66M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 419 | 162.52K | 4.81K | 6.32K | 7.96K | 10.04K |
| Days Sales Outstanding | - | - | - | - | - | 171.25 |
| Inventory | 0 | 0 | 0 | -6.32K | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | -78.02 |
| Other Current Assets | 0 | 0 | 145.14K | 205.18K | 3.13B | 3.18M |
| Total Non-Current Assets | 92.88K | 1.71M | 1.81M | 1.41M | 479.77M | 398.84K |
| Property, Plant & Equipment | 92.88K | 1.23M | 954.07K | 651.27K | 65.4M | 42.8K |
| Fixed Asset Turnover | - | - | - | - | - | 0.08x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 410.8K | 250.32K | 119K | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 71.02K | 609.6K | 638.87K | 414.37M | 1.39M |
| Total Assets | 1.01M▲ 0% | 6.71M▲ 567.1% | 4.6M▼ 31.5% | 4.46M▼ 3.0% | 6.51B▲ 145908.6% | 6.24M▲ 0% |
| Asset Turnover | - | - | - | - | - | 0.00x |
| Asset Growth % | - | 567.1% | -31.48% | -3.04% | 145908.57% | 24.61% |
| Total Current Liabilities | 28.35K | 2.99M | 3.28M | 2.73M | 2.89B | 3.04M |
| Accounts Payable | 194 | 762.2K | 632.82K | 620.48K | 21.66K | 21.05K |
| Days Payables Outstanding | 34.86 | 62.14K | 19.43K | 18.05K | 738.04 | 46.34K |
| Short-Term Debt | 188 | 7.96K | 6.95K | 1.92K | 1.08M | 49.48K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 22.73K | -11.19K | -9.7K | 2.05M | 2.89B | 2.97M |
| Current Ratio | 32.22x | 1.67x | 0.85x | 1.12x | 2.09x | 2.09x |
| Quick Ratio | 32.22x | 1.67x | 0.85x | 1.12x | 2.09x | 2.09x |
| Cash Conversion Cycle | - | - | - | - | - | -46.25K |
| Total Non-Current Liabilities | 1.78K | 232.19K | 18.81K | 64.53K | 145.65M | 193.89K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 139.77K | 0 |
| Capital Lease Obligations | 1.78K | 232.19K | 18.81K | 64.53K | 201 | 101K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 145.65M | 193.89K |
| Total Liabilities | 30.13K | 3.22M | 3.29M | 2.8M | 3.03B | 3.24M |
| Total Debt | 7.21K | 476.83K | 242.33K | 128.66K | 1.26M | 55.84K |
| Net Debt | -58.71K | -4.31M | -2.38M | -2.48M | -2.9B | -2.66M |
| Debt / Equity | 0.01x | 0.14x | 0.19x | 0.08x | 0.00x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | -0.05x |
| Net Debt / EBITDA | - | - | - | - | - | 2.16x |
| Interest Coverage | - | - | - | - | - | - |
| Total Equity | 976.24K▲ 0% | 3.49M▲ 257.7% | 1.31M▼ 62.6% | 1.66M▲ 27.4% | 3.48B▲ 208981.5% | 3M▲ 0% |
| Equity Growth % | - | 257.66% | -62.61% | 27.4% | 208981.45% | 444.58% |
| Book Value per Share | 0.09 | 0.25 | 0.07 | 0.08 | 160.70 | 0.14 |
| Total Shareholders' Equity | 976.24K | 3.49M | 1.31M | 1.66M | 3.48B | 3M |
| Common Stock | 14.72K | 99K | 20K | 20K | 21.64M | 21.64K |
| Retained Earnings | -5.43M | -9.46M | -13.19M | -15.97M | -19.23B | -19.62M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -177.09K | 268.86K | 804.02K | 1.12M | 1.34B | 1.26M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
ADVB Cash Flow Statement
Advanced Biomed Inc. Common Stock (ADVB) cash flow — operating, investing & free cash flow history
| Line item | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|
| Cash from Operations | -473.98K | -741.45K | -2.96M | -2.13M | -181.46K | -181.46K |
| Operating CF Margin % | - | - | - | - | - | - |
| Operating CF Growth % | - | -56.43% | -299.71% | 28.25% | 91.47% | -2656.47% |
| Net Income | -1.84M | -4.03M | -3.73M | -2.78M | -3.26B | -2.33M |
| Depreciation & Amortization | 57.85K | 126.63K | 365.23K | 399.6K | 343.83M | 151.53K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | 1.66M | 150.21K | 0 | 2.92B | -2.98M |
| Working Capital Changes | 1.31M | 1.5M | 253.71K | 256.34K | -90.65K | -139.99K |
| Change in Receivables | 28 | 243 | 21.4K | 53.49K | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 17.24K | 912.42K | 381.25K | 479.63K | -3.67K | -97.7K |
| Cash from Investing | -25.44K | -1.08M | -263.01K | -74.11K | -985 | 7.74K |
| Capital Expenditures | -25.44K | -889.59K | -210.88K | -74.11K | -985 | 9.89K |
| CapEx % of Revenue | - | - | - | - | - | - |
| Acquisitions | 0 | 199.53K | -50.49K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | -393.62K | -1.64K | 0 | 0 | -2.15K |
| Cash from Financing | 697.16K | 6.1M | 458.14K | 1.87M | 184.87K | 6.31M |
| Debt Issued (Net) | 0 | 0 | 0 | 1.66M | 13.72K | 29.23K |
| Equity Issued (Net) | 697.16K | 1000K | 1000K | -2.68K | 171.14K | 178.59K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | -553.47K | 212.18K | 0 | 6.1M |
| Net Change in Cash | 217▲ 0% | 4.72M▲ 2174066.8% | -2.16M▼ 145.8% | -14.31K▲ 99.3% | 19.02K▲ 232.9% | 2.47M▲ 0% |
| Free Cash Flow | -499.42K▲ 0% | -2.05M▼ 311.2% | -3.18M▼ 54.7% | -2.2M▲ 30.7% | -182.45K▲ 91.7% | -1.01M▲ 0% |
| FCF Margin % | - | - | - | - | - | -5896.45% |
| FCF Growth % | - | -311.2% | -54.66% | 30.72% | 91.71% | 37.82% |
| FCF per Share | -0.04 | -0.14 | -0.16 | -0.11 | -0.01 | -0.01 |
| FCF Conversion (FCF/Net Income) | 0.26x | 0.18x | 0.79x | 0.76x | 1.79x | 0.44x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
ADVB Key Ratios
Advanced Biomed Inc. Common Stock (ADVB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Return on Equity (ROE) | -180.3% | -155.62% | -187.43% | -0.01% | -77.48% |
| Return on Invested Capital (ROIC) | -3488.71% | - | - | -0.02% | -0.02% |
| Gross Margin | - | - | - | - | -53.07% |
| Net Margin | - | - | - | - | -13531.65% |
| Debt / Equity | 0.14x | 0.19x | 0.08x | 0.00x | 0.00x |
| FCF Conversion | 0.18x | 0.79x | 0.76x | 1.79x | 0.44x |
ADVB SEC Filings & Documents
Advanced Biomed Inc. Common Stock (ADVB) SEC filings — annual & quarterly reports (10-K, 10-Q)
ADVB Frequently Asked Questions
Advanced Biomed Inc. Common Stock (ADVB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Advanced Biomed Inc. Common Stock (ADVB) reported $0.0M in revenue for fiscal year 2025.
Advanced Biomed Inc. Common Stock (ADVB) grew revenue by 0.0% over the past year. Growth has been modest.
Advanced Biomed Inc. Common Stock (ADVB) reported a net loss of $2.3M for fiscal year 2025.
Dividend & Returns
Advanced Biomed Inc. Common Stock (ADVB) has a return on equity (ROE) of -0.0%. Negative ROE indicates the company is unprofitable.
Advanced Biomed Inc. Common Stock (ADVB) had negative free cash flow of $1.0M in fiscal year 2025, likely due to heavy capital investments.
Explore More ADVB
Advanced Biomed Inc. Common Stock (ADVB) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates